Quick Facts: Uses of Cartia XT

• High Blood Pressure (Hypertension): May support the reduction and management of elevated blood pressure.
• Chronic Stable Angina: May contribute to improved exercise tolerance in individuals experiencing this condition.
• Coronary Artery Spasm (Variant Angina): May help manage symptoms associated with this type of chest discomfort.

---

Cartia XT is a medication indicated for the management of specific cardiovascular conditions. Its primary use is in the treatment of hypertension, a condition where blood pressure is consistently elevated. Regular use may contribute to lowering blood pressure, which is an important component of overall risk management for cardiovascular events.

Additionally, Cartia XT is utilized in the management of chronic stable angina, a form of chest pain or discomfort that may occur with physical activity. For individuals with this condition, the medication may support an improvement in the ability to tolerate exercise. It is also an option for managing angina caused by coronary artery spasm, sometimes referred to as variant angina. This medication should be used as part of a comprehensive, physician-guided care plan. For a complete list of approved indications and safety information, please consult a healthcare provider or professional prescribing resources.

Official Eligibility and Contraindications

The eligibility for using Cartia XT (diltiazem extended-release) is strictly defined by regulatory documents based on the patient’s underlying medical status.

Category	Regulatory Status
Populations for whom use is allowed	Adults for the treatment of hypertension and chronic stable angina.
Age-related eligibility	Safety and effectiveness have not been established for the pediatric population. Caution is advised for older adults due to potential age-related organ impairment.
Conditional Use (Caution Required)	Use requires caution in patients with impaired hepatic (liver) function, impaired renal (kidney) function, or impaired ventricular function (heart failure).
Pregnancy/Lactation Status	Generally not recommended during pregnancy unless the benefit outweighs the risk. A decision must be made to discontinue nursing or discontinue the drug during lactation.

---

Contraindicated Populations

Cartia XT is absolutely contraindicated (must not be used) in patients with the following specific, documented conditions:

• Severe Cardiac Conduction Defects: Sick Sinus Syndrome or Second- or Third-Degree Atrioventricular (AV) Block, unless a functioning ventricular pacemaker is present.
• Hemodynamic Instability: Severe Hypotension (systolic blood pressure less than 90 mm Hg).
• Acute Cardiac Events: Acute Myocardial Infarction (MI) complicated by Pulmonary Congestion.
• Allergy: Known Hypersensitivity to diltiazem hydrochloride.

This structure reflects the regulatory mandate to define populations where the drug’s potential risk outweighs its therapeutic role.

Interactions with other medicines and products

Official regulatory information for this drug, which contains diltiazem, documents several significant interactions primarily based on two mechanisms: its action on cardiac conduction and its effect as a Cytochrome P450 3A4 (CYP3A4) inhibitor.

Cardiovascular and Pharmacodynamic Interactions

The co-administration of Cartia XT with other agents that slow heart rate or impair cardiac conduction, such as beta-blockers (e.g., Metoprolol, Carvedilol), Digitalis (Digoxin), or Clonidine, may result in additive effects, potentially increasing the risk of abnormally slow heart rate (bradycardia) or heart block. Concurrent use of Ivabradine is generally avoided. Use with other antihypertensives or nitrates may enhance blood pressure lowering.

Pharmacokinetic and Metabolic Interactions

Cartia XT inhibits the CYP3A4 enzyme, which is responsible for metabolizing many other medications. This inhibition can lead to increased plasma levels and potential toxicity of co-administered CYP3A4 substrate drugs. Statins like Simvastatin and Lovastatin are CYP3A4 substrates and require monitoring and potential dosage reduction when combined with diltiazem. Other affected medicines include Cyclosporine, Carbamazepine, and certain Benzodiazepines (e.g., Midazolam, Triazolam).

Conversely, strong CYP3A4 inducers, such as the antibiotic Rifampin, can decrease diltiazem's concentration in the body, which is a contraindicated combination. CYP3A4 inhibitors like Cimetidine may increase diltiazem levels.

Food and Substance Interactions

Consumption of Alcohol is discouraged as it may enhance blood pressure lowering effects and alter the drug's extended-release formulation. Excessive consumption of Grapefruit Juice may also increase the drug's plasma concentration.

How Cartia XT Works: Mechanism of Action

Cartia XT (diltiazem) acts as a non-dihydropyridine antagonist of the voltage-dependent L-type slow calcium channels ( CaV1.2) located in both cardiac muscle cells and vascular smooth muscle cells. This action interrupts the flow of extracellular calcium ions ( Ca^2+) into the cytoplasm, a process essential for excitation-contraction coupling.

In vascular smooth muscle, the limitation of intracellular Ca^2+ suppresses the molecular signals required for contraction, resulting in vasodilation and a subsequent decrease in systemic vascular resistance (SVR).

In the heart, this mechanism affects two key areas. In myocardial cells, reduced Ca^2+ entry leads to decreased myocardial contractility. Crucially, in the electrical tissues of the atrioventricular (AV) node, it slows the speed of impulse conduction, resulting in a slower heart rate. The combined effects of reduced SVR, slower rate, and decreased contractility lead to a lower myocardial oxygen demand and a reduction in the heart's overall workload.

Cartia XT is an extended-release capsule that is administered through the oral route. The formulation supports a once-daily dosing regimen, and the dose should be taken at approximately the same time each day to maintain consistent drug levels. The capsule can be administered without regard to meals, meaning it may be taken either with or without food.

To ensure the controlled-release function of the medication is maintained, the capsule must always be swallowed whole. It is explicitly stated that the capsule must not be crushed, chewed, or opened to prevent the rapid release of the entire dose, which is an administration constraint tied directly to the product’s design.

The initial dosage for managing hypertension typically ranges from 180 mg to 240 mg once daily, while the initial dose for angina management is usually 120 mg or 180 mg once daily. Doses are prescribed by a healthcare provider and may be adjusted. However, standard clinical practice specifies that any dosage adjustment should occur over a period of 7 to 14 days to allow the maximum therapeutic effect to be observed before making further changes. The safety and effectiveness of Cartia XT have not been established in pediatric patients.

The overall use protocol is defined by this single, sustained-action administration pattern. This means the medicine is intended for long-term use, and its procedural constraints—swallowing the capsule whole and adhering to the once-daily schedule—are fundamental to ensuring its intended delivery of the active substance.

Research Evidence / Overview of Studies for Cartia XT

Research for Cartia XT (extended-release diltiazem) was conducted for specific cardiovascular conditions characterized by fluctuating or episodic manifestations. The research base is built upon formal clinical trials designed to understand what symptom patterns were observed over time and what physiological measurements were recorded.

---

Evidence Base for High Blood Pressure (Hypertension)

Research for high blood pressure was evaluated in a series of short-term Randomized Controlled Trials (RCTs) in adults with mild to moderate essential hypertension. Researchers primarily monitored outcomes related to systemic or functional imbalance, such as changes in resting and 24-hour ambulatory Systolic and Diastolic Blood Pressure (BP). Studies also examined the consistency of the extended-release capsule, with reports describing the measured drug concentrations over the 24-hour interval.

However, the core controlled trials generally had limited follow-up durations. This means that while research provides insight into short-term changes, there is limited information for long-term outcomes regarding the specific extended-release formulation’s effect on major cardiovascular events. Results apply only to the populations studied.

---

Evidence Base for Chronic Stable Angina

Cartia XT for chronic stable angina pectoris was observed in controlled clinical trials focusing on adults. Primary outcome measures centered on functional capacity, specifically focusing on measured exercise duration and patient-reported outcomes describing perceived discomfort, such as tracking the frequency of anginal episodes. Findings describe patterns observed in the studies in these functional and symptomatic measures during the study period.

The evidence largely relies on these functional measures and short-term symptomatic relief rather than direct data on measured long-term event reduction. Most core efficacy testing covers only a few weeks or months, meaning long-term effects are not fully established and follow-up durations were limited.

---

Areas of Research Uncertainty and Study Gaps

The research base has several acknowledged limitations, including the short follow-up durations of the core efficacy trials for all indications. Furthermore, studies for angina heavily rely on surrogate measures like exercise time rather than direct evidence of measured long-term event reduction. Evidence quality varies across studies, and the findings for less common indications, such as coronary artery spasm, were observed in some studies with smaller participant numbers. Findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.

Key Studies & References Diltiazem Hydrochloride Extended-Release Capsules (Official Prescribing Information)

Common questions about Cartia XT (FAQ)

Q: What is the difference between Cartia XT and standard diltiazem?

A: Cartia XT is documented in official product information as an extended-release formulation of diltiazem hydrochloride. This means the capsule is specifically designed to release the medication slowly and consistently into the bloodstream over a 24-hour period. This design is the key difference from standard diltiazem, which often refers to immediate-release formulations.

---

Q: How long does it typically take for Cartia XT to start working?

A: Due to its extended-release design, the medication is gradually absorbed over a 24-hour cycle to provide continuous support. Official guidance specifies that when a dose is changed, adjustments are recommended to occur over a period of 7 to 14 days. This timeframe allows the full therapeutic effect of the new dose to be observed before making any further changes.

---

Q: Is it normal to feel a little dizzy when first starting Cartia XT?

A: Dizziness is officially documented in the product's adverse reaction profile as a common side effect reported in clinical trials, as are headache and fatigue. While official documentation lists the frequency of side effects, it does not specify the exact timing or duration of onset for common side effects like dizziness.

---

Q: Can Cartia XT affect sleep or cause insomnia?

A: Insomnia, which is difficulty sleeping, is listed in official regulatory documents as an uncommon adverse reaction reported for diltiazem products. Any changes to sleep patterns are a matter for discussion with a healthcare professional.

---

Q: Can Cartia XT be taken during pregnancy?

A: According to official product information, Cartia XT is not generally recommended for use during pregnancy. It should only be used if the potential benefit to the patient is determined to justify the potential risks to the developing fetus.

---

Q: Is Cartia XT safe for breastfeeding mothers?

A: Diltiazem, the active ingredient, is known to pass into human breast milk. Regulatory documents state that a decision must be made to either discontinue nursing or discontinue the drug for the mother, taking into account the drug's importance to the mother's health.

---

Q: Can older adults use Cartia XT safely?

A: Official information indicates that use in older adults requires caution. This is because age-related decreases in the function of the liver or kidneys may affect how the drug is cleared from the body. This potential for reduced clearance may increase the chance of experiencing side effects.

---

Q: Can I take Cartia XT with cold and flu medicine?

A: Cartia XT has documented interactions with numerous other medications, particularly those that can affect the heart rate, blood pressure, or are metabolized by the CYP3A4 enzyme. Many common cold and flu medicines contain active ingredients, such as decongestants, that may fall into these categories. The documentation advises reviewing all non-prescription medicines, including cold and flu remedies, with a health professional for potential drug interactions.

---

Q: Will Cartia XT interact with common herbal supplements?

A: The drug's metabolism and effect can be influenced by substances that affect the CYP3A4 enzyme or heart function, which may include certain herbal supplements. Official documentation does not list specific herbals, but a review of all supplements with a health professional is advised to address potential interactions.

---

Q: Does Cartia XT contain aspirin?

A: The active ingredient in Cartia XT is diltiazem hydrochloride. Official labeling for the product defines all components, and it does not list aspirin as either an active or an inactive ingredient.

---

Q: What happens if I miss a dose of Cartia XT?

A: Regulatory patient information for a missed extended-release dose generally describes taking it as soon as it is remembered, unless it is close to the time of the next scheduled dose. If the next dose is near, the missed dose is typically skipped. Patient materials advise against taking extra doses to compensate for a missed one.

---

Q: What are the signs of taking too much Cartia XT?

A: Official documentation regarding overdosage states that symptoms may include severe drops in blood pressure (hypotension), an abnormally slow heart rate (bradycardia), and serious delays in the heart’s electrical conduction.

---

Q: Does taking Cartia XT require regular blood tests?

A: Official documentation advises that laboratory parameters of kidney and liver function should be monitored at regular intervals for patients taking the drug over prolonged periods. This is because the medication is extensively metabolized by the liver, which requires monitoring.

---

Q: Is Cartia XT known to cause weight gain?

A: Official documentation reports peripheral oedema, which is swelling or fluid retention in the hands, ankles, or feet, as a common side effect. Rapid or sudden significant weight gain, while not a common reported side effect, is listed in safety warnings as a potential symptom of developing heart failure, which warrants professional evaluation.

---

Q: Can Cartia XT cause a rash?

A: Rash is listed as a common adverse reaction in clinical trial reports for diltiazem. Furthermore, the official safety profile documents rare but serious adverse events, including severe cutaneous (skin) reactions like urticaria (hives) and Stevens-Johnson syndrome.

---

Q: Is the tiredness I feel from Cartia XT or something else?

A: The official documentation lists fatigue as a common adverse reaction reported in clinical trials. It is also important to note that fatigue may be a symptom of other medical conditions, including issues with the heart. Any ongoing or concerning fatigue is a matter for review with a healthcare professional.

---

Q: Can Cartia XT be used by teenagers?

A: The safety and effectiveness of Cartia XT have not been established in pediatric patients, which includes the teenage population. For this reason, the use of this medicine is restricted to adults for its approved indications.

---

Q: What are the research themes for Cartia XT use in patients?

A: Official research themes include the drug's effect on physiological measures such as 24-hour ambulatory blood pressure and objective performance measures like exercise duration for stable angina. The limitations of the research, such as the short follow-up durations of the core efficacy trials, are also documented in the official regulatory information.

How to Store and Dispose of Cartia XT

The storage of Cartia XT (Diltiazem Hydrochloride Extended-Release Capsules) must strictly adhere to regulatory labeling requirements to maintain stability.

Official Storage Conditions

Requirement	Details
Temperature	Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F). Permitted excursions are between 15 C and 30 C.
Protection	Keep from freezing; must protect from light and avoid excessive humidity.
Container	Store in a tight, light-resistant container, kept tightly closed.
Child Safety	Mandatory to keep out of the reach of children.

Disposal

To dispose of unused or expired Cartia XT, ask a healthcare professional or pharmacist for instructions. Do not flush the medication down a toilet or pour it down a drain unless specifically advised to do so by a regulatory authority.